Microbix Biosystems Inc.
(MENAFN- Baystreet) 09:40 AM EST - Microbix Biosystems Inc. : And Labquality Oy (Labquality), announce a novel external quality assessment program to help ensure clinical laboratories accurately identify head and neck cancers associated with cancer-causing strains of Human Papilloma Virus. Labquality is introducing this novel EQA scheme at the 2025 meeting of the European Society for Clinical Virology in Thessaloniki, Greece 17-20 September. Microbix Biosystems Inc.
shares T are trading unchanged at $0.23.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Chicago Clearing Corporation And Taxtec Announce Strategic Partnership
- Everstake Expands Institutional Solana Services With Shredstream, Swqos, And Validator-As-A-Service
- Japan Smart Cities Market Size Is Expected To Reach USD 286.6 Billion By 2033 CAGR: 14.6%
- Alchemy Markets Launches Tradingview Integration For Direct Chart-Based Trading
- Blackrock Becomes The Second-Largest Shareholder Of Freedom Holding Corp.
- Pluscapital Advisor Empowers Traders To Master Global Markets Around The Clock
More Story
Comments
No comment